CACYBP: A Protein Targeted for Cancer and Other Diseases (G27101)

Target Name: CACYBP

NCBI ID: G27101

CACYBP

CACYBP: A Protein Targeted for Cancer and Other Diseases

CACYBP is a drug target (or biomarker) that is being studied for its potential in treating various diseases, including cancer. CACYBP is a protein that is expressed in various tissues and cells in the body, including the brain, pancreas , and gastrointestinal tract. It is involved in the regulation of cell growth, apoptosis (programmed cell death), and inflammation.

One of the main focuses of research on CACYBP is its potential as a drug target for cancer. Cancer is a leading cause of death worldwide, and there is a need for new, effective treatments to address the growing number of treatment-resistant cases. CACYBP has been shown to have potential targeting in various types of cancer, including breast, ovarian, and colorectal cancer.

One of the reasons for the potential of CACYBP as a cancer drug target is its involvement in cell apoptosis. Apoptosis is a natural process that helps remove damaged or dysfunctional cells from the body, and it is often triggered by environmental factors or genetic changes. , in cancer cells, apoptosis may not occur properly, leading to the growth and survival of these cells.

CACYBP has been shown to regulate apoptosis in various cell types, including cancer cells. Studies have shown that CACYBP can induce apoptosis in cancer cells, leading to cell death and a reduction in cell population. This has the potential to be a useful mechanism for targeting cancer cells that are resistant to traditional treatments.

Another reason for the potential of CACYBP as a cancer drug target is its involvement in cell growth and proliferation. Cancer cells require constant growth and proliferation in order to maintain their survival, and CACYBP has been shown to be involved in these processes. By inhibiting CACYBP , researchers hope to reduce the ability of cancer cells to grow and multiply.

In addition to its potential as a cancer drug target, CACYBP has also been shown to have potential as a biomarker for various diseases. Its involvement in cell apoptosis and growth may make it a useful indicator of the effectiveness of certain treatments. For example, if a patient experiences an improvement in their apoptosis rates after taking a treatment, this may be a sign that the treatment is having the desired effect.

Overall, CACYBP is a protein that has potential as a drug target and biomarker for various diseases, including cancer. Its involvement in cell apoptosis and growth make it a promising target for researchers to investigate further. As more research is conducted on CACYBP, it is likely that new treatments will be developed that can effectively target cancer cells and improve the quality of life for those suffering from these diseases.

Protein Name: Calcyclin Binding Protein

Functions: May be involved in calcium-dependent ubiquitination and subsequent proteasomal degradation of target proteins. Probably serves as a molecular bridge in ubiquitin E3 complexes. Participates in the ubiquitin-mediated degradation of beta-catenin (CTNNB1)

The "CACYBP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACYBP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets